POST-MARKET SURVEILLANCE DUTIES: LEGAL OBLIGATIONS, REGULATORY OVERSIGHT AND JUDICIAL PRECEDENTS

1. INTRODUCTION

Post-market surveillance (PMS) refers to the continuing monitoring of pharmaceutical products, biological medicines, vaccines, medical devices and other regulated healthcare products after they have received marketing approval and entered commercial distribution.

Regulatory approval does not eliminate the manufacturer's legal responsibility for product safety. Manufacturers, importers, distributors and marketing authorisation holders must monitor adverse events, identify safety signals, investigate product defects, maintain quality standards and take corrective action when risks emerge.

The principal objective of post-market surveillance is to protect patients and consumers against previously unidentified risks, manufacturing defects, product contamination, device failures and misleading safety claims.

In India, post-market surveillance is governed through pharmaceutical legislation, medical-device regulations, pharmacovigilance requirements, consumer-protection law and applicable regulatory directions.

2. LEGAL AND REGULATORY FRAMEWORK IN INDIA

The principal legal instruments include:

A. DRUGS AND COSMETICS ACT, 1940: Establishes regulatory controls concerning the manufacture, sale, distribution and quality of drugs. Non-compliance with applicable statutory standards may attract regulatory and penal consequences.

B. MEDICAL DEVICES RULES, 2017: Establishes regulatory requirements for medical devices, including post-market monitoring, reporting of adverse events, investigation and corrective action.

C. NEW DRUGS AND CLINICAL TRIALS RULES, 2019: Provides the regulatory framework for new drugs and clinical trials, including applicable safety-reporting obligations.

D. CONSUMER PROTECTION ACT, 2019: Provides remedies against defective products, deficient services and unfair trade practices, including product-liability claims where statutory conditions are satisfied.

E. PHARMACOVIGILANCE PROGRAMME OF INDIA (PvPI): Provides a national mechanism for collecting, assessing and communicating information concerning adverse drug reactions.

3. PRINCIPAL POST-MARKET SURVEILLANCE DUTIES

A. ADVERSE EVENT REPORTING

Manufacturers and relevant authorisation holders must comply with applicable requirements for reporting adverse drug reactions, serious adverse events and medical-device incidents. Reports must be submitted within the prescribed timelines.

B. CONTINUOUS SAFETY MONITORING

Companies must monitor safety information arising from healthcare professionals, patients, scientific publications, regulatory communications and post-marketing studies.

C. PRODUCT DEFECT INVESTIGATION

Manufacturers must investigate complaints involving contamination, malfunction, incorrect labelling, packaging defects, manufacturing deviations and unexpected therapeutic failures.

D. PERIODIC SAFETY REPORTING

Where required by applicable regulatory conditions, marketing authorisation holders must prepare and submit periodic safety reports evaluating accumulated safety information and emerging risks.

E. FIELD SAFETY CORRECTIVE ACTION

Where a medical device presents an unacceptable risk, appropriate corrective action may include safety notices, software corrections, device modification, replacement or recall.

F. PRODUCT RECALL

Companies must initiate appropriate recall procedures when products are defective, unsafe, adulterated, spurious or otherwise non-compliant with applicable law.

G. RECORD MAINTENANCE

Relevant safety reports, complaints, investigation findings, corrective actions and regulatory communications must be documented and retained according to applicable legal requirements.

4. IMPORTANT CASE LAWS

1. Indian Medical Association v. V.P. Shantha (1995) — DIRECT CONSUMER-PROTECTION AUTHORITY.

The Supreme Court recognised that medical services can fall within the Consumer Protection Act, subject to the statutory exceptions. The decision provides an important foundation for consumer remedies concerning deficient healthcare services associated with unsafe products.

2. Spring Meadows Hospital v. Harjol Ahluwalia (1998) — ANALOGOUS AUTHORITY.

The Supreme Court recognised consumer remedies arising from medical negligence and deficiency in healthcare services. The decision illustrates the importance of professional responsibility and patient protection.

3. Kusum Sharma v. Batra Hospital (2010) — ANALOGOUS AUTHORITY.

The Supreme Court discussed the principles governing medical negligence and the standard of reasonable professional care. These principles are relevant when assessing whether failures to respond to known product-safety risks amount to negligence.

4. Samira Kohli v. Dr. Prabha Manchanda (2008) — ANALOGOUS AUTHORITY.

The Supreme Court explained the importance of informed consent in medical treatment. Its principles are relevant to communicating material safety information and obtaining appropriate patient consent.

5. Jacob Mathew v. State of Punjab (2005) — ANALOGOUS AUTHORITY.

The Supreme Court clarified principles governing criminal medical negligence. The judgment is relevant when evaluating the legal responsibility of healthcare professionals who handle defective or potentially dangerous products.

6. V. Kishan Rao v. Nikhil Super Speciality Hospital (2010) — ANALOGOUS AUTHORITY.

The Supreme Court explained the application of expert evidence in medical-negligence proceedings. The principles may assist courts examining technical evidence concerning device failures, adverse reactions and safety investigations.

5. LIABILITY FOR FAILURE TO PERFORM SURVEILLANCE DUTIES

Failure to discharge post-market surveillance responsibilities may result in:

Regulatory inspection and investigation.

Suspension or cancellation of manufacturing or marketing permissions.

Mandatory product recall or corrective action.

Financial penalties and prosecution where statutory provisions apply.

Consumer compensation and product-liability proceedings.

Civil liability for negligence or breach of applicable duties.

Reputational damage and restrictions on future commercial activities.

Liability depends on the applicable statutory provision, the party's role, evidence of breach and the causal relationship between the breach and the alleged harm.

6. PRACTICAL COMPLIANCE REQUIREMENTS

Manufacturers and marketing authorisation holders should establish:

A documented pharmacovigilance and device-vigilance system.

Procedures for receiving and investigating safety complaints.

Qualified personnel responsible for safety reporting.

Risk-based monitoring and signal evaluation.

Traceability systems for affected product batches.

Written recall and field-safety corrective-action procedures.

Periodic review of safety data and regulatory obligations.

Appropriate communication with regulators, healthcare professionals and affected patients.

7. CONCLUSION

Post-market surveillance is a continuing legal and regulatory responsibility rather than a voluntary quality-management activity. Manufacturers, importers and marketing authorisation holders must identify emerging safety risks, investigate adverse events, maintain accurate records and take timely corrective action. Indian pharmaceutical and medical-device regulations, together with consumer-protection principles and judicial precedents, establish an important framework for accountability. Effective surveillance protects patients, improves product reliability and ensures that regulatory approval remains supported by continuing evidence of safety and quality.